Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Jun 29, 2007
Cambridge University Alliance
May 31, 2007
First patient enters Glypromate Phase 3 trial
May 22, 2007
Revised Constitution
May 22, 2007
2007 AGM Results
May 22, 2007
CEO Presentation AGM
May 14, 2007
Bachem Glypromate Collaboration
May 10, 2007
Clinical Trials Update May 2007
Apr 30, 2007
Commitments Test Entity - First Quarter Report
Apr 24, 2007
Notice of Annual General Meeting
Mar 29, 2007
Annual Report
Previous
1
2
3
4
5
6
Next